Escalation with overdose control using time to toxicity for cancer phase I clinical trials.
about
Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.The rapid enrollment design for Phase I clinical trials.A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.
P2860
Escalation with overdose control using time to toxicity for cancer phase I clinical trials.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Escalation with overdose contr ...... ancer phase I clinical trials.
@ast
Escalation with overdose contr ...... ancer phase I clinical trials.
@en
type
label
Escalation with overdose contr ...... ancer phase I clinical trials.
@ast
Escalation with overdose contr ...... ancer phase I clinical trials.
@en
prefLabel
Escalation with overdose contr ...... ancer phase I clinical trials.
@ast
Escalation with overdose contr ...... ancer phase I clinical trials.
@en
P2093
P2860
P1433
P1476
Escalation with overdose contr ...... ancer phase I clinical trials.
@en
P2093
André Rogatko
Mourad Tighiouart
P2860
P304
P356
10.1371/JOURNAL.PONE.0093070
P407
P577
2014-03-24T00:00:00Z